Cargando…

Clinical Scenarios for Discordant Anti-Xa

Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review...

Descripción completa

Detalles Bibliográficos
Autores principales: Vera-Aguilera, Jesus, Yousef, Hindi, Beltran-Melgarejo, Diego, Teng, Teng Hugh, Jan, Ramos, Mok, Mary, Vera-Aguilera, Carlos, Moreno-Aguilera, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880685/
https://www.ncbi.nlm.nih.gov/pubmed/27293440
http://dx.doi.org/10.1155/2016/4054806
_version_ 1782433831323697152
author Vera-Aguilera, Jesus
Yousef, Hindi
Beltran-Melgarejo, Diego
Teng, Teng Hugh
Jan, Ramos
Mok, Mary
Vera-Aguilera, Carlos
Moreno-Aguilera, Eduardo
author_facet Vera-Aguilera, Jesus
Yousef, Hindi
Beltran-Melgarejo, Diego
Teng, Teng Hugh
Jan, Ramos
Mok, Mary
Vera-Aguilera, Carlos
Moreno-Aguilera, Eduardo
author_sort Vera-Aguilera, Jesus
collection PubMed
description Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice.
format Online
Article
Text
id pubmed-4880685
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48806852016-06-12 Clinical Scenarios for Discordant Anti-Xa Vera-Aguilera, Jesus Yousef, Hindi Beltran-Melgarejo, Diego Teng, Teng Hugh Jan, Ramos Mok, Mary Vera-Aguilera, Carlos Moreno-Aguilera, Eduardo Adv Hematol Review Article Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice. Hindawi Publishing Corporation 2016 2016-05-12 /pmc/articles/PMC4880685/ /pubmed/27293440 http://dx.doi.org/10.1155/2016/4054806 Text en Copyright © 2016 Jesus Vera-Aguilera et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Vera-Aguilera, Jesus
Yousef, Hindi
Beltran-Melgarejo, Diego
Teng, Teng Hugh
Jan, Ramos
Mok, Mary
Vera-Aguilera, Carlos
Moreno-Aguilera, Eduardo
Clinical Scenarios for Discordant Anti-Xa
title Clinical Scenarios for Discordant Anti-Xa
title_full Clinical Scenarios for Discordant Anti-Xa
title_fullStr Clinical Scenarios for Discordant Anti-Xa
title_full_unstemmed Clinical Scenarios for Discordant Anti-Xa
title_short Clinical Scenarios for Discordant Anti-Xa
title_sort clinical scenarios for discordant anti-xa
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880685/
https://www.ncbi.nlm.nih.gov/pubmed/27293440
http://dx.doi.org/10.1155/2016/4054806
work_keys_str_mv AT veraaguilerajesus clinicalscenariosfordiscordantantixa
AT yousefhindi clinicalscenariosfordiscordantantixa
AT beltranmelgarejodiego clinicalscenariosfordiscordantantixa
AT tengtenghugh clinicalscenariosfordiscordantantixa
AT janramos clinicalscenariosfordiscordantantixa
AT mokmary clinicalscenariosfordiscordantantixa
AT veraaguileracarlos clinicalscenariosfordiscordantantixa
AT morenoaguileraeduardo clinicalscenariosfordiscordantantixa